Allergy Therapeutics (LON:AGY) Stock Price Down 7.8% – What’s Next?

Shares of Allergy Therapeutics plc (LON:AGY) were down 7.8% during mid-day trading on Monday . The company traded as low as GBX 9.60 and last traded at GBX 10. Approximately 241,736 shares changed hands during trading, a decline of 13% from the average daily volume of 278,121 shares. The stock had previously closed at GBX 10.85.

Allergy Therapeutics Stock Performance

The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The stock’s 50-day moving average price is GBX 10.73 and its 200-day moving average price is GBX 10.46. The company has a market capitalization of £633.25 million, a price-to-earnings ratio of -10.31, a P/E/G ratio of -30.70 and a beta of 0.91.

Allergy Therapeutics (LON:AGY) last released its quarterly earnings data on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. The business had revenue of GBX 3,628 million during the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. As a group, equities research analysts expect that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.